![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » BIOSCRIP DIPS TO LOSS IN Q4 ON CHARGE
BIOSCRIP DIPS TO LOSS IN Q4 ON CHARGE
March 29, 2006
Wednesday morning, BioScrip Inc., a pharmaceutical care company, announced fourth quarter results, reporting a loss compared to a profit in the year-ago quarter, primarily on an asset impairment charge, accounting compliance costs and merger related expenses. The New-York based company reported a net loss for the fourth quarter of $22.62 million or $0.61 per share compared to a net income of $1.19 million or $0.05 per share in the prior year-quarter.
Trading Markets (http://www.tradingmarkets.com/tm.site/news/BREAKING%20NEWS/206320/)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct